TrialCancer medicine2026

Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High-Risk Recurrence Factors: A Phase II Single-Center Prospective Study.

Yitong Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.